Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2019-12-01 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
WHITE APPLICATION FORM
Share Issue/Capital Change Classification · 95% confidence The document is an application form for the Hong Kong Offer Shares of Alphamab Oncology, referencing the company's prospectus dated December 2, 2019. It contains detailed instructions on how to apply for shares, payment methods, and legal disclaimers related to the offering. This is clearly related to a share issuance process and not a financial report, management announcement, or other regulatory filing. The document is not a report itself but an application form for a share offering, which fits the category of Share Issue/Capital Change announcements. Therefore, the appropriate classification is SHA (Share Issue/Capital Change). The document length and content confirm it is not a brief announcement but a detailed application form, supporting high confidence in this classification.
2019-12-01 English
GLOBAL OFFERING
Share Issue/Capital Change Classification · 95% confidence The document is a landing page or index for a 'Global Offering' prospectus for Alphamab Oncology. It lists various sections of a prospectus, including 'Financial Information', 'Accountants' Report', and 'Structure of the Global Offering'. Since this is an announcement/index page for a prospectus (a document related to a new share issuance/IPO), and it serves as a portal to the actual offering documents, it falls under the category of a regulatory filing related to capital raising. Given the specific options, 'RNS' (Regulatory Filings) is the most appropriate fallback for this type of announcement page.
2019-12-01 English
GLOBAL OFFERING
Regulatory Filings
2019-12-01 English
GLOBAL OFFERING
Capital/Financing Update Classification · 95% confidence The document is an announcement related to a Global Offering of shares by Alphamab Oncology, including details about the number of shares offered, offer price, application procedures, and regulatory disclaimers. It references the prospectus and provides information on the public offering and international offering, including the over-allotment option and listing details. There is no financial performance data, earnings information, or management discussion. The document is a formal announcement about the capital raising event and share issuance, not a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, supporting a high confidence in this classification.
2019-12-01 English
PHIP (1st submission)
Audit Report / Information Classification · 95% confidence The document is a PHIP (Post-Hearing Information Proof) for Alphamab Oncology, which is a standard regulatory filing document used in the Hong Kong Stock Exchange (HKEX) listing process. It contains a table of contents for a prospectus, including sections like 'Business', 'Financial Information', and 'Accountants' Report'. Since it is a listing-related document that does not fit into the other specific categories like 10-K or IR, and serves as a regulatory disclosure for a potential IPO, it is classified as a Regulatory Filing (RNS). 9M 2019
2019-11-17 English
PHIP (1st submission)
Regulatory Filings Classification · 95% confidence The document is titled 'Post Hearing Information Pack' and is issued by Alphamab Oncology in connection with a securities offering. It contains disclaimers about the document being in draft form, incomplete, and subject to change. The text repeatedly emphasizes that it is not a prospectus or an offer to sell securities, and it references regulatory bodies such as The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission. The document discusses the expected timetable for a public offering and includes details about share pricing, underwriting, and legal disclaimers related to securities laws. This type of document is typically part of the regulatory process for a public listing or securities offering and is not a final report or financial statement. It is an informational pack provided post-hearing with regulators, often as part of the listing or offering process. Given the nature of the document as an informational pack related to a securities offering and the emphasis on regulatory compliance and disclaimers, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and filings that do not fit other specific categories. The document is lengthy (15,000 characters) and contains substantive information but is not a financial report, earnings release, or prospectus itself.
2019-11-17 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.